Search
for

    Learn

    5 / 801 results

      learn Pyrilutamide

      highly targeted anti-androgen that might have minimal systemic effects

      learn Cyproterone

      a synthetic anti-androgen and weak progestogen that inhibits DHT binding to androgen receptor

      learn PP405

      mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials

    Research

    5 / 51 results

    Community Join

    5 / 1000+ results

      community The New, Improved CB-03-01/Setipiprant Group Buy

       27 upvotes 9 years ago
      The group buy for CB-03-01, a topical anti-androgen for hair loss, was postponed and refunded due to issues with the product's form and solubility. The product, also known as Breezula, is an alternative to finasteride with fewer side effects, but its official release is delayed until 2021.

      community DLQ01: A Better "Minoxidil" PGF2a synthetic analogue.

      in Research/Science  3 upvotes 1 year ago
      DLQ01, a prostaglandin F2α analog, shows promise for hair growth by directly stimulating PGE2/PGF receptors without needing conversion, and can be combined with minoxidil and retinoids like tretinoin for enhanced effectiveness. Minoxidil's efficacy may be reduced by COX-1 inhibitors, but using prostaglandin analogs like Latanoprost or Bimatoprost can help maintain its effectiveness.

      community Best Treatment In The Pipeline?

      in Chat  15 upvotes 1 year ago
      New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.
      FCE 28260: A Forgotten 5α-Reductase Inhibitor

      community FCE 28260: A Forgotten 5α-Reductase Inhibitor

      in Research  330 upvotes 1 year ago
      FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

      community Why is there no feedback on pge2/setipiprant?

      in Question  6 upvotes 9 years ago
      The conversation questions the lack of feedback on the effectiveness of PGE2 and setipiprant for hair loss, despite their availability. The user is puzzled by the absence of reviews or results, whether positive or negative.